Welcome
The Vaccine and Gene Therapy Institute at Oregon Health & Science University has assembled a multidisciplinary team of scientists to respond to serious viral disease threats, including AIDS, chronic viral infection-associated diseases, newly emerging viral diseases and infectious diseases of the elderly. Our programs are intended to span the continuum between basic and clinical science, in which discoveries are rapidly advanced from the level of molecular and cellular biology through animal models and ultimately into clinical testing. Learn more
VGTI Seminar Series
Recent publications
PLoS Pathog. December 11, 2024
Viral microRNA regulation of Akt is necessary for reactivation of Human Cytomegalovirus from latency in CD34+ hematopoietic progenitor cells and humanized mice
J Virol. December 10, 2024
Third intracellular loop of HCMV US28 is necessary for signaling and viral reactivation
JCI Insight. December 6, 2024
Rapid systemic spread and minimal immune responses following SIVsab intrarectal transmission in African green monkeys
Nat Commun. December 4, 2024
Potent AMA1-specific human monoclonal antibody against Plasmodium vivax Pre-erythrocytic and Blood Stages
J Med Chem. December 2, 2024
4-Substituted-2-Thiazole Amides as Viral Replication Inhibitors of Alphaviruses
bioRxiv. November 27, 2024
Systemic exposure to COVID-19 virus-like particles modulates firing patterns of cortical neurons in the living mouse brain
Front Immunol. November 26, 2024
Effects of COVID-19 virus-like particles on the behavioral and cognitive performance of human apolipoprotein E targeted replacement mice
Nat Protoc. November 21, 2024
Biolayer interferometry for measuring the kinetics of protein-protein interactions and nanobody binding
Res Sq. November 12, 2024
A Covalent Chemical Probe for Chikungunya nsP2 Cysteine Protease with Antialphaviral Activity and Proteome-wide Selectivity
Clin Ther. November 2024
A Randomize Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19
PLoS Pathog. November 11, 2024
A model of lymphocryptovirus-associated post-transplant lymphoproliferative disorder in immunosuppressed Mauritian cynomolgus macaques
J Infect Dis. October 28, 2024
Impact of Dolutegravir plus Lamivudine as First-Line Antiretroviral Treatment on HIV-1 Reservoir and Inflammatory Markers in Peripheral Blood
Curr Opin HIV AIDS. October 22, 2024
Stem cell transplantation and allogeneic immunity: post treatment control or HIV cure?
Cancers (Basel). October 19, 2024
Functional Targets for Epstein-Barr Virus BART MicroRNAs in B Cel Lymphomas
Front Immunol. October 15, 2024
Functional genomic analysis of the 68-1 RhCMV-Mycobacteria tuberculosis vaccine reveals an IL-15 response signature that is conserved with vector attenuation
Proc Natl Acad Sci USA. October 15, 2024
Identification of a cell-active chikungunya virus nsP2 protease inhibitor using a covalent fragment-based screening approach.
Sci Immunol. October 11, 2024
Human cytomegalovirus UL18 prevents priming of MHC-E- and MHC-II-restricted CD8+ T cells.
Microbiol Spectr. September 30, 2024
Pre-challenge gut microbial signature predicts RhCMV/SIV vaccine efficacy in rhesus macaques
Mabs. September 26, 2024
FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques
BioDrugs. September 18, 2024
Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure
Nat Immunol. September 12, 2024
Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption
Ways to Give
Donate to Vaccine and Gene Therapy Institute.
VGTI offers two options and account to consider when donating that serve differing purposes:
The VGTI Support Foundation Fund
Gifts to the VGTI Support Foundation Fund provides vital support that allows us find cures for life threatening infectious diseases. These funds help us to have necessary resources and create and conduct innovative infectious disease research studies, leading to the development of vaccines and cures.
The Jay Nelson Memorial Fund
Gifts to the Jay Nelson Memorial Fund supports providing education and learning opportunities for our current up and coming scientists with a focus on Herpesvirus.
Biographical Feature:
In memoriam Jay A. Nelson (1948–2024)
Your Gift Brings Hope, Please support our mission in memory of Jay Nelson. Your generosity will help support education and learning opportunities for our current up and coming scientists with a focus on Herpesvirus. Click to Donate
The VGTI Support Foundation Fund
Donate to VGTI
Your gifts help provide vital resources to conduct innovative research and more.
COVID-19 Efforts - Building a COVID Testing Lab